^
Association details:
| Biomarker: | IDH2 mutation + Chr del(1p) + Chr del(19q) |
|---|---|
| Cancer: | Glioma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Revolumab: A phase II trial of nivolumab in recurrent IDH-mutant high-grade gliomas
Published date:
05/26/2022
Excerpt:
...39 patients with recurrent IDH-mutant HGG...n = 10 1p/19q- codeleted...According to RANO, one patient (2.6%) achieved complete response (CR), 3 patients (7.7%) partial response (PR), 13 patients (33.3%) stable disease, and 22 (56.4%) had progression as their best response. Median PFS and OS were 1.84 (CI95% [1.81 ; 5.89]) and 14.7 months (CI95% [9.18; NR]), respectively.
DOI:
10.1200/JCO.2022.40.16_suppl.2048
Trial ID:
